Paul Feuerstadt, MD: The Future of C Difficile Treatment

We may soon be entering a new era of treatments for Clostridioides difficile infections (CDI).

What started with fecal microbiota transplantation (FMT), soon became live microbiome therapeutics (LMT).

This could include multiple LMT’s to garner full US Food and Drug Administration (FDA) approval in the coming year or 2.

And from there, the expectation is companies will continue to evolve the treatments and learn from what is working.

One such drug is RBX2660, a standardized, stabilized, investigational microbiota-based live therapeutic. Currently, standard-of-care for patients with recurrent C difficile infections is antibiotics, with consideration of fecal microbiota transplantation (FMT) following multiple recurrences.

In an interview with HCPLive®, Paul Feuerstadt, MD, Assistant Clinical Professor of Medicine, Yale School of Medicine, said not only is RBX2660 on the precipice of improving care for patients with recurrent C difficile infections, but there are several other similar treatments in production.

Feuerstadt also spoke about the need to really examine how we are treating patients.

“I think we’re really shifting our focus with treatment,” he said. “Previously, it was well if you have some infection or some disease, we need to get you treated. I think we are shifting to where yes we need to get you treated, but why don’t we focus on risk factor management, why don’t we focus on weight reduction, why don’t we focus on cardiovascular exercise.”